Amarin Corp Plc (AMRN)

[Whalatane]

N7 / RMB. N7 thx for the link. Interesting read
Rose If Kaiser finds significant benefits in the population studied … basically ASCVD patients around 70 yrs old .. I expect them to release top line data as soon as it’s available, announce details to be presented at a later conference plus in the NEJM , and move to get all their patients that fit the trials inclusion data … on Vascepa

If data is “ mixed “ they may wait until a conference to present .

Kaiser does not make a lot of $ having their ICU’s clogged with Covid patients on O2 support
My wife worked for them
They make $ in billable procedures .. turnover of patients like CAD patients that need stents
Get them in , put in some stents , get them out … next customer please .

If MITIGATE shows benefit they will want their ASCVD patients on Vascepa ASAP

Kiwi